Moderna shares posted one of their best gains in nearly two months as the vaccine developer said it advanced several pipeline candidates into late-stage clinical trials, including a next-generation Covid-19 vaccine. The drugmaker also announced up to $750 million in funding from Blackstone Life Sciences to help fund development for its flu program.